7-氰基-4-(苯基甲氧基)-2-萘羧酸乙酯 | 178877-04-8

• 分子结构分类: 有机化合物 - 苯类化合物 - 萘
• 中文名称: 7-氰基-4-(苯基甲氧基)-2-萘羧酸乙酯
• 英文名称: ethyl 1-benzyloxy-6-cyano-3-naphthalenecarboxylate
• 英文别名: ethyl 4-Benzyloxy-7-cyano-2-naphthalenecarboxylate；2-Naphthalenecarboxylic acid, 7-cyano-4-(phenylmethoxy)-, ethyl ester；ethyl 7-cyano-4-phenylmethoxynaphthalene-2-carboxylate
• CAS: 178877-04-8
• 化学式: C₂₁H₁₇NO₃
• 分子量: 331.371
• InChiKey: RPHGKNFYBZWEEL-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  4.6
• 重原子数：
  25
• 可旋转键数：
  6
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.14
• 拓扑面积：
  59.3
• 氢给体数：
  0
• 氢受体数：
  4

反应信息

• 作为反应物：
  描述：

  7-氰基-4-(苯基甲氧基)-2-萘羧酸乙酯 在 lithium hydroxide monohydrate 、 盐酸 作用下， 以 四氢呋喃 、 甲醇 、 水 为溶剂， 反应 2.0h， 以87%的产率得到7-氰基-4-(苯基甲氧基)-2-萘羧酸
  参考文献：
  名称：

  基于细胞毒性抗生素 Duocarmycin 的荧光标记糖苷前药的合成

  摘要：

  描述了在2中芳族A环的不同位置用不同荧光染料标记的糖苷前药(1S)-30a、(1S,10R)-30b和(1S,10R)-32的合成；这些化合物在结构上基于细胞毒性抗生素 duocarmycin SA。为了结合，氨基化合物(1S)-3a和(1S，10R)-3b分别用染料5-SFX (29)和D10162 (31)的市售琥珀酰亚胺处理。

  DOI：

  10.1002/ejoc.201000966
• 作为产物：
  描述：

  7-溴-4-羟基-2-萘羧酸乙酯 在 四丁基碘化铵 、 potassium carbonate 作用下， 以 N,N-二甲基甲酰胺 为溶剂， 反应 31.0h， 生成 7-氰基-4-(苯基甲氧基)-2-萘羧酸乙酯
  参考文献：
  名称：

  Synthesis, Chemical Properties, and Preliminary Evaluation of Substituted CBI Analogs of CC-1065 and the Duocarmycins Incorporating the 7-Cyano-1,2,9,9a-tetrahydrocyclopropa[c]benz[e]indol-4-one Alkylation Subunit:  Hammett Quantitation of the Magnitude of Electronic Effects on Functional Reactivity

  摘要：

  The synthesis of 7-cyano-1,2,9,9a-tetrahydrocyclopropa[c]benz[e]indol-4-one (CCBI), a substituted CBI derivative bearing a C7 cyano group, is described in efforts that establish the magnitude of potential electronic effects on the functional reactivity of the agents. The CCBI alkylation subunit was prepared by a modified Stobbe condensation/Friedel-Crafts acylation for generation of the appropriately functionalized naphthalene precursors followed by 5-exo-trig aryl radical-alkene cyclization for synthesis of the 1,2-dihydro-3H-benz[e]indole skeleton and final Ar-3' alkylation for introduction of the activated cyclopropane. The most concise approach provided the CCBI subunit and its immediate precursor in 14-15 steps in superb overall conversions (15-20%). Resolution of an immediate CCBI precursor and its incorporation into both enantiomers of 34-39, analogs of CC-1065 and the duocarmycins, are detailed. A study of the solvolysis reactivity and regioselectivity of N-BOC-CCBI (25) revealed that introduction of the C7 nitrile slowed the rate of solvolysis but only to a surprisingly small extent. Classical Hammett quantitation of the effect provided a remarkably small rho (-0.3), indicating an exceptionally small C7 substituent electronic effect on functional reactivity. Additional kinetic studies of acid-catalyzed nucleophilic addition proved inconsistent with C4 carbonyl protonation as the slow and rate-determining step but consistent with a mechanism in which protonation is rapid and reversible followed by slow and rate-determining nucleophilic addition to the cyclopropane requiring both the presence and assistance of a nucleophile (S(N)2 mechanism). No doubt this contributes to the DNA alkylation selectivity of this class of agents and suggests that the positioning of an accessible nucleophile (adenine N3) and not C4 carbonyl protonation is the rate-determining step controlling the sequence selectivity of the DNA alkylation reaction, This small electronic effect on the solvolysis rate had no impact on the solvolysis regioselectivity, and stereoelectronically-controlled nucleophilic addition to the least substituted carbon of the activated cyclopropane was observed exclusively. Consistent with past studies, a direct relationship between solvolysis stability and cytotoxic potency was observed with the CCBI-derived agents providing the most potent analogs in the CBI series, and these observations were related to the predictable Hammett substituent effects. For the natural enantiomers, this unusually small electronic effect on functional reactivity had no perceptible effect on their DNA alkylation selectivity. Similar effects of the C7 cyano substituent on the unnatural enantiomers were observed, and they proved to be 4-10x more effective than the corresponding CBI-based unnatural enantiomers and 4-70x less potent than the CCBI natural enantiomers.

  DOI：

  10.1021/jo9605298

文献信息

• Analogs of CC-1065 and the duocarmycins
  申请人：The Scripps Research Institute

  公开号：US06060608A1

  公开（公告）日：2000-05-09

  Analogs of antitumor antibiotics CC-1065 and the duocarmycins are synthesized which possess systematic and extensive modifications in the DNA binding subunits attached to a 1,2,9,9a-tetra-hydro-cyclo-propa[c]benz[e]indol-4-one (CBI) alkylation subunit. The analogs have potent cytotoxic activity and are efficacious antitumor compounds.

  合成了抗肿瘤抗生素CC-1065和二聚卡蜜辛的类似物，这些类似物在与1,2,9,9a-四氢-环丙烯基苯并[c]吲哚-4-酮（CBI）烷基化亚单位结合的DNA结合亚单位中进行了系统和广泛的修饰。这些类似物具有强效的细胞毒活性，并且是有效的抗肿瘤化合物。
• Cyclopropylindole derivatives
  申请人：Thurston David Edwin

  公开号：US06909006B1

  公开（公告）日：2005-06-21

  Compounds of formula (III) or (V), wherein is a solid support; L is a linking group or a single bond; T is a combinatorial unit; n is a positive integer, where if n is greater than 1, each T may be different: X is an electrophilic leaving group; Y is selected from NH-Prot, O-Prot, S-Prot, NO 2 , —NHOH. N 3 , NHR, NRR, N═NR, N(O)RR, NHSO 2 R, N═N═PhR, SR or SSR, where Prot represents a protecting group; A and B collectively represent a fused benzene or pyrrole ring (in either orientation), which is optionally substituted by up to respectively 4 or 2 groups independently selected from R, OH, OR, halo, nitro, amino, Me 3 Sn, CO 2 H, CO 2 R, R 1 is a nitrogen protecting group, where if Y includes a protecting group, these protecting groups are orthogonal and R 2 and R 7 are independently selected from H, R, OH, OR, halo, nitro, amino, Me 3 Sn, and other related compounds and collections of compounds.

  式（III）或（V）的化合物中，其中是固体支撑；L是连接基团或单键；T是组合单元；n是正整数，如果n大于1，则每个T可能不同：X是亲电离开基团；Y从NH-Prot、O-Prot、S-Prot、NO2、—NHOH、N3、NHR、NRR、N═NR、N（O）RR、NHSO2R、N═N═PhR、SR或SSR中选择，其中Prot代表保护基团；A和B共同代表一个融合的苯或吡咯环（在任何方向），可选地由最多分别从R、OH、OR、卤、硝基、氨基、Me3Sn、CO2H、CO2R中独立选择的4个或2个基团取代，R1是氮保护基团，如果Y包括保护基团，则这些保护基团是正交的，R2和R7分别独立选择自H、R、OH、OR、卤、硝基、氨基、Me3Sn和其他相关化合物和化合物集合。
• EP0934269A4
  申请人：——

  公开号：EP0934269A4

  公开（公告）日：2000-01-12
• ANALOGS OF CC-1065 AND THE DUOCARMYCINS
  申请人：The Scripps Research Institute

  公开号：EP0934269A1

  公开（公告）日：1999-08-11
• US6060608A
  申请人：——

  公开号：US6060608A

  公开（公告）日：2000-05-09